Business

Announcement on Voluntary Disclosure of Top-line Analysis Data of Phase III Clinical Trial of Chidamide as the First-line Treatment for Diffuse Large B-cell Lymphoma

Announcement on Voluntary Disclosure of Top-line Analysis Data of Phase III Clinical Trial of Chidamide as the First-line Treatment for Diffuse Large B-cell Lymphoma

articleShenzhen Chipscreen Biosciences Co. Ltd. Class AJuly 9, 20254/news/announcement-on-voluntary-disclosure-of-top-line-analysis-data-of-phase-iii-clinical-trial-of-chidamide-as-the-first-line-treatment-for-diffuse-large-b-cell-lymphoma
Announcement on Voluntary Disclosure of Top-line Analysis Data of Phase III Clinical Trial of Chidamide as the First-line Treatment for Diffuse Large B-cell Lymphoma

About this update from Shenzhen Chipscreen Biosciences Co. Ltd. Class A

Announcement on Voluntary Disclosure of Top-line Analysis Data of Phase III Clinical Trial of Chidamide as the First-line Treatment for Diffuse Large B-cell LymphomaThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Shenzhen Chipscreen Biosciences Co. Ltd. Class A